Drug Profile
GSK 2256294
Alternative Names: GSK-2256294Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiasthmatics
- Mechanism of Action Epoxide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 06 Apr 2018 Vanderbilt University Medical Center plans a phase II trial in healthy volunteers in USA, in April 2018 (NCT03486223)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In the elderly, In volunteers) in USA (PO, Capsule)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in United Kingdom (PO, Capsule)